Targeted Therapeutics Research Award
Funded equally by LUNGevity Foundation and the American Lung Association
George C. Prendergast, PhD
Lankenau Institute for Medical Research
Wynnewood
PA
The IDO protein stops immune cells from recognizing cancer cells and mounting an attack against the cancer. Dr. Prendergast is determining how the IDO protein works in non-small cell lung cancer cells that have mutations in the KRAS gene. He is also testing new compounds that can inhibit IDO in non-small cell lung cancer.